Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class Resolvin Oral Therapy for Crohn’s Disease

RIDGEFIELD, CT AND NEW YORK, NY – (April 5, 2022) – Thetis Pharmaceuticals (“Thetis”), a pioneering therapeutics biotechnology company developing a first-in-class small molecule (TP-317) as a potential oral first-line therapy for treatment of Crohn’s disease, has secured $4.2 million in non-dilutive financing from The Leona M. and Harry B. Helmsley Charitable Trust. Structured as […]